- Home
- MGNX vs MX Comparison
MGNX vs MX Comparison
Compare MGNX & MX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- MX
- Stock Information
- Founded
- MGNX 2000
- MX 2003
- Country
- MGNX United States
- MX South Korea
- Employees
- MGNX N/A
- MX N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- MX Semiconductors
- Sector
- MGNX Health Care
- MX Technology
- Exchange
- MGNX Nasdaq
- MX Nasdaq
- Market Cap
- MGNX 99.7M
- MX 103.8M
- IPO Year
- MGNX 2013
- MX N/A
- Fundamental
- Price
- MGNX $1.76
- MX $3.21
- Analyst Decision
- MGNX Hold
- MX Strong Buy
- Analyst Count
- MGNX 5
- MX 2
- Target Price
- MGNX $3.25
- MX $5.75
- AVG Volume (30 Days)
- MGNX 582.9K
- MX 446.9K
- Earning Date
- MGNX 08-14-2025
- MX 07-31-2025
- Dividend Yield
- MGNX N/A
- MX N/A
- EPS Growth
- MGNX N/A
- MX N/A
- EPS
- MGNX N/A
- MX N/A
- Revenue
- MGNX $165,495,000.00
- MX $234,243,000.00
- Revenue This Year
- MGNX N/A
- MX N/A
- Revenue Next Year
- MGNX N/A
- MX $7.05
- P/E Ratio
- MGNX N/A
- MX N/A
- Revenue Growth
- MGNX 303.47
- MX 16.02
- 52 Week Low
- MGNX $0.99
- MX $2.51
- 52 Week High
- MGNX $5.10
- MX $5.16
- Technical
- Relative Strength Index (RSI)
- MGNX 57.55
- MX 51.71
- Support Level
- MGNX $1.69
- MX $2.67
- Resistance Level
- MGNX $1.87
- MX $3.30
- Average True Range (ATR)
- MGNX 0.12
- MX 0.14
- MACD
- MGNX 0.02
- MX 0.08
- Stochastic Oscillator
- MGNX 71.59
- MX 85.16
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About MX Magnachip Semiconductor Corporation
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The company operates in two segments namely, Transitional Fab 3 foundry services and Standard products business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.